{"id":49977,"date":"2020-05-05T00:00:00","date_gmt":"2020-05-04T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/the-fda-licenses-chemotargets-clarity-platform\/"},"modified":"2020-11-18T15:09:27","modified_gmt":"2020-11-18T14:09:27","slug":"the-fda-licenses-chemotargets-clarity-platform","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/","title":{"rendered":"The FDA licenses Chemotargets CLARITY platform"},"content":{"rendered":"<p>The Food and Drug Administration (<a href=\"https:\/\/www.fda.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">FDA<\/a>) Center for Drug Evaluation and Research (<a href=\"https:\/\/www.fda.gov\/about-fda\/fda-organization\/center-drug-evaluation-and-research-cder\" target=\"_blank\" rel=\"noopener noreferrer\">CDER)<\/a> has licensed the Chemotargets CLARITY<sup>\u00ae<\/sup>\u00a0platform for predicting unknown secondary targets for new molecules of pharmaceutical interest.<\/p>\n<p>This contract is meant to directly address the FDA\u2019s requirement for a computational method which can predict potential molecular targets from chemical structure and provide a user-friendly environment for analysis of results. Molecular targets identified with high confidence by CLARITY<span style=\"font-size: 10.5px;line-height: 0;vertical-align: baseline\">\u00ae<\/span> may be evaluated by FDA\/CDER for their association with adverse events, addiction liability, or their association with disease within the specified indication(s).<\/p>\n<p>A previous collaboration with FDA\/CDER focused on predicting on-target and off-target activities using known in vitro pharmacology data for small molecules and associating them with drug safety data coming from post-marketing spontaneous reports. A tangible outcome of the collaboration between FDA\/CDER and Chemotargets has been the incorporation of CLARITY<span style=\"font-size: 10.5px;line-height: 0;vertical-align: baseline\">\u00ae<\/span>\u00a0as part of the FDA\u2019s Public Health Assessment via Structural Evaluation (PHASE) initiative for assessing the abuse risk that new drugs could pose to public safety <em>(<\/em><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30957872\" target=\"_blank\" rel=\"noopener noreferrer\"><em>Clin. Pharmacol. Ther. <\/em>2019, 106, 116-122<\/a> and <a href=\"https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0229646\" target=\"_blank\" rel=\"noopener noreferrer\"><em>PLoS ONE <\/em>2020, 15, e0229646<\/a>).<\/p>\n<p>Chemotargets CLARITY<sup>\u00ae<\/sup> (which was awarded the <a href=\"https:\/\/www.chemotargets.com\/News\/id\/99\/chemotargets-clarity-has-been-awarded-the-seal-of-excellence-from-the-european-commission\" target=\"_blank\" rel=\"noopener noreferrer\">Seal of Excelence<\/a> from the European Commission)\u00a0uses artificial intelligence on carefully-curated data to connect molecules, protein targets, safety events, and therapeutic indications with the help of state-of-the-art analytics tools. Beyond a knowledge-based source that can be interrogated from any discovery angle, the platform can be used to identify the probable primary and secondary targets of small molecules and their predicted metabolites by rapidly profiling through consensus ligand-based models of 4,799 proteins built from affinity data for almost 3 million small molecules.<\/p>\n<p>In addition, machine learning models of 1,278 safety endpoints were constructed from data carefully extracted from almost 16 million spontaneous reports, including hundreds of safety-related mechanisms annotated with preclinical toxicity and clinical safety issues.<\/p>\n<p>Chemotargets\u00a0was founded in March 2006 by Dr. Jordi Mestres as a spin-off from the Hospital del Mar Medical Research Institute\u00a0(<a href=\"https:\/\/www.imim.es\/\" target=\"_blank\" rel=\"noopener noreferrer\">IMIM<\/a>), a leading health research institute\u00a0based in Barcelona (Spain). Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by new methods generated at Dr Mestres\u2019\u00a0<a href=\"http:\/\/syspharm.imim.cat\/\" target=\"_blank\" rel=\"noopener noreferrer\">Systems Pharmacology Lab<\/a>.<\/p>\n<p>The\u00a0<a href=\"http:\/\/www.prousresearch.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Prous Institute for Biomedical Research\u00a0<\/a>has made a strategic investment in Chemotargets\u00a0which has allowed CLARITY<sup>\u24c7<\/sup>\u00a0product development to be accelerated and new capabilities to be acquired in order to support the company\u2019s vision and quickly address customer needs. The company also has the\u00a0advice and support of\u00a0<a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_007135&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3DGENESIS%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">GENESIS Biomed,<\/a>\u00a0a well-established consultancy firm in the health and biotech sectors, and\u00a0<a href=\"http:\/\/www.creainversion.com\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">CREA Inversi\u00f3n<\/a>, an M&amp;A boutique advisory firm specialised in corporate transactions and financing.<\/p>\n<p>\n<strong>\u25ba<a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/noticies\/-\/noticia\/not_chemotargets-obre-una-ronda-d-inversio-per-fer-front-a-una-nova-etapa-de-creixement?backURL=%2Fportal%2Fes%2Fel-pcb%23sala-premsa\" target=\"_blank\" rel=\"noopener noreferrer\">\u00a0Related news [+]<\/a><\/strong><\/p>\n<p style=\"font-size:12pt;font-family:Times New Roman, serif;text-align:justify\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_006013&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dchemotargets%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">Chemotargets<\/a>\u00a0\u2013a global leader in the development of intelligence platforms and drug design prediction, headquartered in the Barcelona Science Park\u2013 has signed a license agreement for its <a href=\"https:\/\/www.chemotargets.com\/PRODUCTS\/CLARITY-v4\" target=\"_blank\" rel=\"noopener noreferrer\">CLARITY<sup>\u00ae<\/sup><\/a><span style=\"font-size: 10.5px\"> <\/span>platform with the Food and Drug Administration (<a href=\"https:\/\/www.fda.gov\/about-fda\/fda-organization\/center-drug-evaluation-and-research-cder\" target=\"_blank\" rel=\"noopener noreferrer\">FDA<\/a>) to provide adverse event predictions and mechanistic investigation in public health risk assessments of new drug applications and existing marketed products.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":54880,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49977","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The FDA licenses Chemotargets CLARITY platform - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA licenses Chemotargets CLARITY platform - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Chemotargets\u00a0\u2013a global leader in the development of intelligence platforms and drug design prediction, headquartered in the Barcelona Science Park\u2013 has signed a license agreement for its CLARITY\u00ae platform with the Food and Drug Administration (FDA) to provide adverse event predictions and mechanistic investigation in public health risk assessments of new drug applications and existing marketed products. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-04T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-18T14:09:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/05\/16057085675fb52b17a6310.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1155\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"The FDA licenses Chemotargets CLARITY platform\",\"datePublished\":\"2020-05-04T23:00:00+00:00\",\"dateModified\":\"2020-11-18T14:09:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/\"},\"wordCount\":446,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/16057085675fb52b17a6310.jpeg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/\",\"name\":\"The FDA licenses Chemotargets CLARITY platform - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/16057085675fb52b17a6310.jpeg\",\"datePublished\":\"2020-05-04T23:00:00+00:00\",\"dateModified\":\"2020-11-18T14:09:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/16057085675fb52b17a6310.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/16057085675fb52b17a6310.jpeg\",\"width\":2000,\"height\":1155},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/the-fda-licenses-chemotargets-clarity-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA licenses Chemotargets CLARITY platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The FDA licenses Chemotargets CLARITY platform - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/","og_locale":"en_US","og_type":"article","og_title":"The FDA licenses Chemotargets CLARITY platform - Parc Cient\u00edfic de Barcelona","og_description":"Chemotargets\u00a0\u2013a global leader in the development of intelligence platforms and drug design prediction, headquartered in the Barcelona Science Park\u2013 has signed a license agreement for its CLARITY\u00ae platform with the Food and Drug Administration (FDA) to provide adverse event predictions and mechanistic investigation in public health risk assessments of new drug applications and existing marketed products. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2020-05-04T23:00:00+00:00","article_modified_time":"2020-11-18T14:09:27+00:00","og_image":[{"width":2000,"height":1155,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/05\/16057085675fb52b17a6310.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"The FDA licenses Chemotargets CLARITY platform","datePublished":"2020-05-04T23:00:00+00:00","dateModified":"2020-11-18T14:09:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/"},"wordCount":446,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/05\/16057085675fb52b17a6310.jpeg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/","url":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/","name":"The FDA licenses Chemotargets CLARITY platform - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/05\/16057085675fb52b17a6310.jpeg","datePublished":"2020-05-04T23:00:00+00:00","dateModified":"2020-11-18T14:09:27+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/05\/16057085675fb52b17a6310.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2020\/05\/16057085675fb52b17a6310.jpeg","width":2000,"height":1155},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/the-fda-licenses-chemotargets-clarity-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"The FDA licenses Chemotargets CLARITY platform"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=49977"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49977\/revisions"}],"predecessor-version":[{"id":54879,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49977\/revisions\/54879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/54880"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=49977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=49977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=49977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}